Patients limited by a RHR of ≤ 55 bpm while not on BB therapy at target dosages showed the lowest risk (NYHA-class: III/IV:33.4%, NT-proBNP 949 pg/ml (Q1-Q3:389–1659; p < 0.0001 comparison for both between all groups), while patients limited by an eGFR ≤ 30ml/min/1.73m2 while not on RASi/MRA therapy at target dosages were characterized by most advanced HF (NYHA-class: III/IV: 62.7%; NT-proBNP 6866 pg/ml (Q1-Q3:3392–14531); p < 0.0001 comparison for both between all groups). This evidence concerns the gene NPPB and hydrops fetalis.